论文部分内容阅读
目的研究英夫利西(类克)对治疗类风湿关节炎的疗效及安全性。方法对14例类风湿关节炎患者使用类克治疗,进行为期半年前瞻性临床观察研究,共静脉点滴5次类克,每次剂量为3mg/kg。同期记录患者的关节肿胀数,关节疼痛数,疼痛视觉模拟评分法(VAS)(100mm)。RA病情活动标准(DAS28)进行活动性评价。同时监测血沉ESR,血常规,尿常规,肝,肾功能等。数据经SPSS11.5软件进行统计学处理。结果治疗26周后,多数患者症状及体检(关节肿胀数,关节疼痛数,疼痛视觉模拟评分法(VAS))较治疗前有明显的改善(P<0.01),血沉,DAS28较治疗前也有明显的改善(P<0.01)。所有患者血尿常规,肝肾功能均未见异常。发现3例不良反应:寒战,皮疹。结论类克可改善大多数患者的症状和体征,起效快,降低ESR,具有较好的安全性。应注意少数患者第二次使用后可能出现轻中度的过敏反应,需停药及时抗过敏处理。
Objective To study the efficacy and safety of infliximab in the treatment of rheumatoid arthritis. Methods 14 cases of rheumatoid arthritis patients treated with class g, for a period of six months of prospective clinical observation of co-venous drip five times grams, each dose of 3mg / kg. The patient’s joint swelling, joint pain and pain visual analogue scale (VAS) (100 mm) were recorded at the same time. RA disease activity standard (DAS28) activity evaluation. At the same time ESR ESR, blood, urine, liver, kidney function and so on. Data were statistically processed by SPSS11.5 software. Results After 26 weeks of treatment, symptoms and physical examination (joint swelling, joint pain, pain visual analogue scale (VAS)) in most patients were significantly improved (P <0.01), and ESR and DAS28 were also significantly higher than those before treatment Improvement (P <0.01). All patients with hematuria, liver and kidney function were normal. Three adverse reactions were found: chills, rashes. Conclusion Gram-like can improve the symptoms and signs of most patients, rapid onset, reduce ESR, with good safety. Should pay attention to a small number of patients may appear after the second use of mild to moderate allergic reactions, need to stop treatment in time anti-allergy.